In a blow to the pharmaceutical industry, the U.S. Food and Drug Administration today announced it is requiring new warnings on testosterone replacement therapy drugs because of increased risks of dangerous venous blood clots.
Currently, testosterone replacement drugs carry a warning about increased risks of blood clots in men who have the disease polycythemia, which produces an increased proportion of red blood cells. The move by the FDA today requires a broader warning of blood clot risks, and not just one related to that condition.
The FDA announced in January that it was reviewing the safety of testosterone replacement therapies based on the findings of two studies that demonstrated so-called Low T drugs greatly increased the risks of heart attacks, strokes, and other cardiovascular events in older men.
That review is continuing, the FDA said in announcing the new warnings.
The news also comes on the heels of numerous lawsuits against testosterone replacement drug makers and marketers.
Ross Feller Casey, a leading personal injury law firm in Philadelphia with a national reputation for winning record results, has already filed six testosterone lawsuits.
Those cases involve men from Alabama, New Jersey, Pennsylvania, Virginia, Texas, and Michigan who suffered a stroke, heart attacks, severe heart damage, pulmonary embolism or cardiac death, while on testosterone drugs.
Ross Feller Casey is currently reviewing many other injuries reported by men across the nation and plans to bring other testosterone lawsuits soon.
If you or a loved one has suffered serious medical affects after taking AndroGel or any other similar testosterone drug, please contact the Ross Feller Casey testosterone lawyers for a free case evaluation.
The firm handles cases, including Low T lawsuits, on a contingency basis, so you will not pay anything unless a recovery is made on your behalf.